1. In Vivo
  2. >>Business Strategy

MedTech Forum 2019: Consumers And Wellness, Or Patients And Health Care?

Medtech's Future Hinges On How The Sector Can Change With The Times

 
• By Ashley Yeo

As health care transitions to digitally enabled wellness, medtechs will be missing a trick if they persist in holding onto the delivery, business methods and models that were the standard of the early 2000s. Heightened expectations of the new options for dealing with personal health mean that new opportunities are there for the taking – but industry shouldn’t let the tech companies have it all their own way, advised ZS principal Brian Chapman.

The MedTech Forum, Medtech Europe’s annual conference, was uprooted for the first time in its history, shifting from Brussels to Paris for 2019. The change of location worked well: by tacking the already populous event onto the back of the French industry association's (Snitem) annual start-ups forum (Journée Start-up innovantes du dispostif médical) attendee numbers swelled nicely. (Also see "French Minister Has Her Own Angle On the Success Of Medtech" - Medtech Insight, 30 May, 2019.)

And the French delegates offered fresh ideas on innovation and uptake, and especially on digital innovation, as the health care...

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.